Trial reportLeukemia research2013
Modest activity of pomalidomide in patients with myelofibrosis and significant anemia.
Trial report in Leukemia research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.Leukemia · 2018Guideline
- Trial
- Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis.Haematologica · 2015Trial
- Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia.Leukemia research · 2014Trial
- NK Cells in Myeloproliferative Neoplasms (MPN).Cancers · 2021Review
- Guideline on myeloproliferative neoplasms: Associacão Brasileira de Hematologia, Hemoterapia e Terapia Cellular: Project guidelines: Associação Médica Brasileira - 2019.Hematology, transfusion and cell therapy · 2019Article
- Management of Myelofibrosis-Related Cytopenias.Current hematologic malignancy reports · 2018Review
- Myelofibrosis: an update on drug therapy in 2016.Expert opinion on pharmacotherapy · 2016Review
- Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.Cancer chemotherapy and pharmacology · 2016Review
- Profile of pomalidomide and its potential in the treatment of myelofibrosis.Therapeutics and clinical risk management · 2015Review
- Durable Red Blood Cell Transfusion Independence in a Patient with an MDS/MPN Overlap Syndrome Following Discontinuation of Iron Chelation Therapy.Case reports in hematology · 2015Article
- Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasms.Current hematologic malignancy reports · 2014Review
- Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes.International journal of general medicine · 2014Article
- Managing Patients With Myelofibrosis in the Era of Janus Kinase Inhibitors.Journal of the advanced practitioner in oncologyReview
- Primary myelofibrosis: current therapeutic options.Revista brasileira de hematologia e hemoterapiaArticle
Corrections and comments
- Commented on by
Authors and funding
12 authors.
Funding
Abstract
We evaluated single agent pomalidomide for myelofibrosis-associated anemia. First, 21 patients received pomalidomide 3.0mg/day on 21-day-on/7-day-off schedule. Due to poor tolerance the study was quickly suspended. Second, 29 patients received pomalidomide 0.5mg/day continuously. Three patients (10%) experienced clinical improvement in hemoglobin per International-Working-Group criteria (median time to response 1.6 months; median response duration 6.7 months). Ten patients were RBC-transfusion-dependent per Delphi criteria; 2 (20%) achieved RBC-transfusion-independence (time to response 0.9 months in both; response duration of 8.3 and 15 months). One grade 3/4 toxicity (neutropenia) occurred. Pomalidomide at low dose is well tolerated but has modest clinical activity in myelofibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.